Business Context and Reporting Period
This Form 8-K was filed by Landec Corporation on May 29, 2009. The report discloses a material definitive agreement entered into by Landec Ag, Inc., a subsidiary of Landec Corporation, with Monsanto Company. The filing amends a License, Supply and R&D Agreement originally executed on December 1, 2006.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to the terms of the amended agreement:
- Original Buy-Out Fee: $8,000,000
- Amended Buy-Out Fee: $10,000,000 (conditional)
Material Changes
The primary material change is the amendment to the "Buy-Out Option" held by Monsanto Company:
- Condition: If the sale of Landec Ag to Monsanto is treated as an acquisition of assets for U.S. federal income tax purposes, the Buy-Out Fee increases from $8,000,000 to $10,000,000.
- Scope: This amendment applies to the option Monsanto holds to purchase all outstanding shares of Landec Ag's capital stock within the five-year period following the original 2006 agreement.
Guidance, Outlook, and Risks
The filing contains no management guidance, financial outlook, or discussion of general business risks. The document notes that the summary of terms is qualified in its entirety by reference to the full text of the Amendment (Exhibit 10.26). No unusual items or contingencies beyond the tax treatment of the potential asset acquisition are disclosed in this summary.
Investor Verification Checklist
- Verify the full text of the First Amendment (Exhibit 10.26) to understand all conditions attached to the $10,000,000 fee increase.
- Confirm the current tax status of a potential asset acquisition of Landec Ag to determine if the higher fee is applicable.
- Review the original December 1, 2006 License Agreement to understand the remaining timeline for the Buy-Out Option.
- Note that this filing does not contain updated financial statements; refer to the most recent 10-K or 10-Q for financial health metrics.